Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 1
2006 3
2007 2
2008 2
2009 2
2010 3
2011 4
2012 6
2013 2
2014 6
2015 11
2016 9
2017 16
2018 12
2019 9
2020 20
2021 16
2022 14
2023 25
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
The third Intensive Care Bundle with Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT3): an international, stepped wedge cluster randomised controlled trial.
Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, Li Q, Malavera A, Li X, Muñoz-Venturelli P, de Silva A, Thang NH, Wahab KW, Pandian JD, Wasay M, Pontes-Neto OM, Abanto C, Arauz A, Shi H, Tang G, Zhu S, She X, Liu L, Sakamoto Y, You S, Han Q, Crutzen B, Cheung E, Li Y, Wang X, Chen C, Liu F, Zhao Y, Li H, Liu Y, Jiang Y, Chen L, Wu B, Liu M, Xu J, You C, Anderson CS; INTERACT3 Investigators. Ma L, et al. Lancet. 2023 Jul 1;402(10395):27-40. doi: 10.1016/S0140-6736(23)00806-1. Epub 2023 May 25. Lancet. 2023. PMID: 37245517 Free PMC article. Clinical Trial.
Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial.
Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, Jiang M, Bai H, Lang T, Wang J, Liu L, Yang T, Huang X, Liu F, Lou S, Liu Y, Zhang C, Liu H, Gao L, Liu J, Zhu L, Wen Q, Chen T, Wang P, Rao J, Mao M, Wang C, Duan X, Luo L, Peng X, Cassady K, Zhong JF, Zhang X. Gao L, et al. Among authors: luo l. J Clin Oncol. 2020 Dec 20;38(36):4249-4259. doi: 10.1200/JCO.19.03277. Epub 2020 Oct 27. J Clin Oncol. 2020. PMID: 33108244 Free PMC article. Clinical Trial.
How does nitrogen shape plant architecture?
Luo L, Zhang Y, Xu G. Luo L, et al. J Exp Bot. 2020 Jul 25;71(15):4415-4427. doi: 10.1093/jxb/eraa187. J Exp Bot. 2020. PMID: 32279073 Free PMC article. Review.
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies.
Li S, Wang X, Liu L, Liu J, Rao J, Yuan Z, Gao L, Li Y, Luo L, Li G, Li Z, Li S, He J, Zhang L, Chen L, Huang W, Yin P, Li C, Li X, Wang Y, Dong Y, Zhang D, Zang Q, Chen Y, Shen L, Li W, Cao W, Zhang X, Wang S. Li S, et al. Among authors: luo l. Leukemia. 2023 Nov;37(11):2176-2186. doi: 10.1038/s41375-023-02018-4. Epub 2023 Sep 12. Leukemia. 2023. PMID: 37700087
Durable remission related to CAR-T persistence in R/R B-ALL and long-term persistence potential of prime CAR-T.
Shiqi L, Jiasi Z, Lvzhe C, Huailong X, Liping H, Lin L, Qianzhen Z, Zhongtao Y, Junjie S, Zucong C, Yingzi Z, Meiling W, Yunyan L, Linling W, Lihua F, Yingnian C, Wei Z, Yu L, Le L, Youcheng W, Dingsong Z, Yancheng D, Ping Y, Lihua Z, Xiaoping L, Xiaozhuang H, Zhongzheng Z, Zhi Y, Cheng Q, Sanbin W. Shiqi L, et al. Among authors: le l. Mol Ther Oncolytics. 2023 Apr 20;29:107-117. doi: 10.1016/j.omto.2023.04.003. eCollection 2023 Jun 15. Mol Ther Oncolytics. 2023. PMID: 37215385 Free PMC article.
DNA nanopores as artificial membrane channels for bioprotonics.
Luo L, Manda S, Park Y, Demir B, Sanchez J, Anantram MP, Oren EE, Gopinath A, Rolandi M. Luo L, et al. Nat Commun. 2023 Sep 4;14(1):5364. doi: 10.1038/s41467-023-40870-1. Nat Commun. 2023. PMID: 37666808 Free PMC article.
160 results